Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1485-1496

  Pauwels, Bea ^a   Wouters, An ^a   Peeters, Marc ^a   Vermorken, Jan B ^a   Lardon, Filip ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

cell cycle; chemoradiation; chemotherapy; radiosensitization; radiotherapy

Indexed keywords

7 METHYLTHIOMETHYLPACLITAXEL; ANTINEOPLASTIC AGENT; BLEOMYCIN; CETUXIMAB; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE; CYCLINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLOXURIDINE; FLUDARABINE; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IRINOTECAN; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; TOPOTECAN; VINFLUNINE;

APOPTOSIS; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL KILLING; CELL PROLIFERATION; CELL REGENERATION; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; RADIOSENSITIVITY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY;

EID: 77957965367     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.104     Document Type: Review

References (58)

1. Gregoire V, Baumann M: Combined radiotherapy and chemotherapy. In: Basic Clinical Radiobiology (4th Edition). Van der Kogel A, Joiner M (Eds). Hodder Arnold, UK, 246-258 (2009).
2. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5(1), 85-91 (1979).
3. Wouters BG, Begg A: Irradiation-induced damage and the DNA damage response. In: Basic Clinical Radiobiology (4th Edition). Van der Kogel A, Joiner M (Eds). Hodder Arnold, UK, 11-26 (2009)
4. Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature 432(7015), 316-323 (2004).
5. DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol.Cell Biol. 15(8), 4215-4224 (1995).
6. Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102(1), 55-66 (2000).
7. Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5(10), 792-804 (2004).
8. 2 inhibition. Mol. Cell Biol. 24(14), 6268-6277 (2004).
9. Zips D: Tumour growth and response to radiation. In: Basic Clinical Radiobiology (4th Edition). Van der Kogel A, Joiner M (Eds). Hodder Arnold, London, 78-101 (2009)
10. Milas L, Mason KA, Liao Z, Ang KK: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck. 25(2), 152-167 (2003).
11. Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7(8), 2168-2181 (2001).
12. Terasima T, Tolmach LJ: Variation in several responses of HeLa cells to X-irradiation during the division cycle. Biophys. J. 3, 11-33 (1963).
13. McGinn CJ, Shewach DS, Lawrence TS: Radiosensitizing nucleosides. J. Natl Cancer Inst. 88(17), 1193-1203 (1996).
14. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach S: Radiosensitization of pancreatic cancer cells by 2́,2́-difluoro-2́-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 34(4), 867-872 (1996).
15. Shewach DS, Lawrence TS: Antimetabolite radiosensitizers. J. Clin. Oncol. 25(26), 4043-4050 (2007).
16. Hwang HS, Davis TW, Houghton JA, Kinsella TJ: Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res. 60(1), 92-100 (2000).
17. Kuo ML, Kunugi KA, Lindstrom MJ, Kinsella TJ: The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. Cancer J. Sci. Am. 3(3), 163-173 (1997).
18. Pauwels B, Korst A, Lardon F, Vermorken J: Combined modality therapy of gemcitabine and radiation. Oncologist 10(1), 34-51 (2005).
19. Pauwels B, Korst AEC, Pattyn GGO et al.: Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int. J. Radiat. Oncol. Biol. Phys. 57(4), 1075-1083 (2003).
20. Morgan MA, Parsels LA, Maybaum J, Lawrence TS: Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin. Cancer Res. 14(21), 6744-6750 (2008).
21. Gregoire V, Van NT, Stephens LC et al.: The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res. 54(23), 6201-6209 (1994).
22. Kruczynski A, Barret JM, Etievant C et al.: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol. 55(5), 635-648 (1998). (Pubitemid 28077822)
23. Kruczynski A, Colpaert F, Tarayre JP et al.: Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol. 41(6), 437-447 (1998).
24. Edelstein MP, Wolfe LA 3rd, Duch DS: Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin. Oncol. 23(2 Suppl. 5), 41-47 (1996)
25. Fukuoka K, Arioka H, Iwamoto Y et al.: Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34(3), 451-460 (2001).
26. Simoens C, Lardon F, Pauwels B et al.: Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 8, 65-77 (2008).
27. Simoens C, Vermorken JB, Korst AE et al.: Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother. Pharmacol. 58(2), 210-218 (2006).
28. Fukuoka K, Arioka H, Iwamoto Y et al.: Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells. Cancer Chemother. Pharmacol. 49(5), 385-390 (2002).
29. Grau C, Hoyer M, Overgaard J: The in vivo interaction between vincristine and radiation in a C3H mammary carcinoma and the feet of CDF1 mice. Int. J. Radiat. Oncol. Biol. Phys. 30(5), 1141-1146 (1994).
30. Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 9(2 Suppl. 1), 12-26 (1999).
31. Hennequin C, Giocanti N, Favaudon V: S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer 71(6), 1194-1198 (1995).
32. Hennequin C, Giocanti N, Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 56(8), 1842-1850 (1996).
33. Kim JS, Amorino GP, Pyo H et al.: The novel taxane analogs, BMS-184476 and BMS- 188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 51(2), 525-534 (2001).
34. Kawato Y, Furuta T, Aonuma M et al.: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol. 28(3), 192-198 (1991).
35. Rich TA: Camptothecin radiation sensitization. In: Chemoradiation in Cancer Therapy (Volume ). Choy H (Ed.). Humana Press, NJ, USA, 93-105 (2003)
36. Boothman DA, Wang M, Schea RA et al.: Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24(5), 939-948 (1992).
37. Chen AY, Okunieff P, Pommier Y, Mitchell JB: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 57(8), 1529-1536 (1997).
38. Minehan KJ, Bonner JA: The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. Life Sci. 53(15), L237-L242 (1993).
39. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V: DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res. 53(9), 2105-2111 (1993).
40. Shigematsu N, Kawata T, Ihara N et al.: Effect of combined treatment with radiation and low dose etoposide on cell survival. Anticancer Res. 21(1A), 325-328 (2001).
41. Bonner JA, Lawrence TS: Doxorubicin decreases the repair of radiation-induced DNA damage. Int. J. Radiat. Biol. 57(1), 55-64 (1990).
42. Byfield JE, Lee YC, Tu L: Molecular interactions between adriamycin and x-ray damage in mammalian tumor cells. Int. J. Cancer 19(2), 186-193 (1977).
43. Kimler BF, Leeper DB: The effect of adriamycin and radiation on G2 progression. Cancer Res. 36(9 Pt 1), 3212-3216 (1976).
44. Supiot S, Gouard S, Charrier J et al.: Mechanisms of cell sensitization to a radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin. Cancer Res. 11(19 Pt 2), S7047-S7052 (2005).
45. Midander J, Littbrand B, Edsmyr F: Irradiation combined with bleomycin treatment of synchronized cells in culture under oxic and hypoxic conditions. Acta Radiol. Oncol. 19(5), 395-400 (1980).
46. Bleehen NM, Gillies NE, Twentyman PR: The effect of bleomycin and radiation in combination on bacteria and mammalian cells in culture. Br. J. Radiol. 47(558), 346-351 (1974).
47. Vanuytsel L, Feng Y, Landuyt W, Leer JW, van der Schueren E: The combined effect of bleomycin and irradiation on mouse lip mucosa. 2. Influence on the accumulation and repair of sublethal damage during fractionated irradiation. Radiother. Oncol. 6(4), 267-273 (1986). (Pubitemid 16026732)
48. Baumann M, Krause M, Dikomey E et al.: EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol. 83(3), 238-248 (2007).
49. Giovannetti E, Mey V, Nannizzi S et al.: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol. 68(1), 110-118 (2005).
50. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D: Interaction of pemetrexed disodium (Alimta, multitargeted antifolate) and irradiation in vitro. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1381-1388 (2002).
51. Bischof M, Huber P, Stoffregen C, Wannenmacher M, Weber KJ: Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int. J. Radiat. Oncol. Biol. Phys. 57(1), 289-292 (2003).
52. Chen YC, Pandya K, Keng PC et al.: Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin. Cancer Res. 9(3), 969-975 (2003).
53. Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3(4), 513-519 (2004).
54. Tenzer A, Pruschy M: Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr. Med. Chem. Anticancer Agents 3(1), 35-46 (2003).
55. Powell SN, DeFrank JS, Connell P et al.: Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55(8), 1643-1648 (1995).
56. Bracey TS, Williams AC, Paraskeva C: Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin. Cancer Res. 3(8), 1371-1381 (1997).
57. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 2(5), 791-797 (1996).
58. Playle LC, Hicks DJ, Qualtrough D, Paraskeva C: Abrogation of the radiationinduced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. Br. J. Cancer 87(3), 352-358 (2002).